Caribou Biosciences Inc (CRBU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Caribou Biosciences Inc (CRBU) has a cash flow conversion efficiency ratio of -0.170x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.82 Million) by net assets ($122.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Caribou Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Caribou Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CRBU total debt and obligations for a breakdown of total debt and financial obligations.
Caribou Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caribou Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daesung Ind
KO:128820
|
0.000x |
|
Sri Rejeki Isman(Sritex)PT
JK:SRIL
|
0.007x |
|
Daehan Flour Mills Co Ltd
KO:001130
|
0.036x |
|
Aplicaciones y Tratamiento de Sistemas S.A.
MC:ATSI
|
0.029x |
|
Deutsche Konsum REIT AG
XETRA:DKG
|
0.035x |
|
Universal Microelectronics Co Ltd
TW:2413
|
0.141x |
|
DAE HWA Pharmaceutical Co. Ltd
KQ:067080
|
0.026x |
|
Elanders AB (publ)
ST:ELAN-B
|
0.064x |
Annual Cash Flow Conversion Efficiency for Caribou Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Caribou Biosciences Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Caribou Biosciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $122.17 Million | $-110.99 Million | -0.908x | -66.28% |
| 2024-12-31 | $252.95 Million | $-138.20 Million | -0.546x | -115.75% |
| 2023-12-31 | $368.40 Million | $-93.29 Million | -0.253x | +16.24% |
| 2022-12-31 | $300.87 Million | $-90.97 Million | -0.302x | -260.58% |
| 2021-12-31 | $387.82 Million | $-32.52 Million | -0.084x | -105.92% |
| 2020-12-31 | $-23.44 Million | $-33.22 Million | 1.417x | +133.05% |
| 2019-12-31 | $7.46 Million | $-32.01 Million | -4.289x | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapse… Read more